SG Americas Securities LLC Sells 260,544 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

SG Americas Securities LLC cut its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 98.8% in the first quarter, Holdings Channel reports. The firm owned 3,081 shares of the company’s stock after selling 260,544 shares during the quarter. SG Americas Securities LLC’s holdings in Centessa Pharmaceuticals were worth $122,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CNTA. Foresite Capital Management VI LLC boosted its holdings in Centessa Pharmaceuticals by 4.8% during the third quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock worth $31,865,000 after buying an additional 60,640 shares during the last quarter. Cinctive Capital Management LP acquired a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth about $2,246,000. Sofinnova Investments Inc. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $27,618,000. Royce & Associates LP increased its stake in shares of Centessa Pharmaceuticals by 46.7% in the 4th quarter. Royce & Associates LP now owns 362,873 shares of the company’s stock valued at $9,075,000 after acquiring an additional 115,486 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $961,000. Institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

CNTA has been the topic of several recent analyst reports. Stephens lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Needham & Company LLC lowered shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target on the stock. in a research report on Monday, April 13th. Finally, Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price target for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $40.50 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.74 and a 52 week high of $40.56. The company’s 50 day moving average price is $39.98 and its two-hundred day moving average price is $32.77. The company has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.